Table 4.

Pooled AIR and cumulative amount of FVIII in PwHAs without FVIII inhibitors across 24-week treatment intervals in the HAVEN 3 and 4 studies

Treatment for bleedWeeks 1-24Weeks 25-48Weeks 49-72Weeks 73-96Weeks 97-120Weeks 121-144
Evaluable participants, n 186 182 175 154 127 112 
FVIII AIR 3.3 (0.8-9.2) 3.7 (0.9-9.8) 3.4 (0.8-9.4) 2.1 (0.3-7.4) 2.0 (0.2-7.2) 2.5 (0.4-8.0) 
FVIII, U/kg 101.6 (82.8-123.4) 107.6 (88.3-130.0) 100.4 (81.7-122.1) 62.9 (48.3-80.5) 56.7 (42.9-73.5) 71.5 (55.9-90.2) 
Treatment for bleedWeeks 1-24Weeks 25-48Weeks 49-72Weeks 73-96Weeks 97-120Weeks 121-144
Evaluable participants, n 186 182 175 154 127 112 
FVIII AIR 3.3 (0.8-9.2) 3.7 (0.9-9.8) 3.4 (0.8-9.4) 2.1 (0.3-7.4) 2.0 (0.2-7.2) 2.5 (0.4-8.0) 
FVIII, U/kg 101.6 (82.8-123.4) 107.6 (88.3-130.0) 100.4 (81.7-122.1) 62.9 (48.3-80.5) 56.7 (42.9-73.5) 71.5 (55.9-90.2) 

Unless otherwise noted, data are mean (95% CI).

A total of 191 PwHAs without FVIII inhibitors were included in the efficacy analysis, because 1 participant in HAVEN 3 assigned to no prophylaxis was lost to follow-up and not treated. This patient was excluded from the efficacy analysis.

or Create an Account

Close Modal
Close Modal